UNSPSC 51172006: Alibendol

This classification denotes a cholagogue or choleretic agent with the molecular formula C13H17NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A8CO1VZK2Z, chemically known as m-anisamide, 5-allyl-2-hydroxy-n-(2-hydroxyethyl)- (8ci) but generally known as alibendol, which bears US NIH Compound Identifier 71916. European Medicines Agency schedules Alibendol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05323MIG.

UNSPSC 51172006 Alibendol, a Commodity code, encompasses drug testing and pharmaceutical supply services actually being procured by state and local health, criminal justice, and purchasing agencies. The code covers both specimen collection and drug screening (immunoassay and confirmatory testing with LC/MS/MS or GC/MS), as well as generic pharmaceutical and over-the-counter product supply through authorized wholesale channels. Issuing bodies include county criminal justice departments, state health and human services commissions, and multi-state cooperative purchasing alliances coordinating procurement across participating state and local facilities. Collin County Community Supervision and Corrections Department in Texas and the Texas Health and Human Services Commission represent repeat engagement with the code's scope, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administers purchasing for multiple jurisdictions including Oregon.

Recent activity concentrates in Texas and the upper Midwest. Collin County posted RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services with proposals due July 23, 2026, covering staffing at two collection sites, immunoassay screening with confirmatory testing, and oral fluid and hair testing methodologies; the estimated contract value is $600,000 over two years with optional renewals, and the county anticipates award August 10, 2026. MMCAP issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) and maintain cGMP and DSCSA compliance; contract terms are two years for new vendors with optional extensions through June 30, 2028. The Texas Health and Human Services Commission posted RFI HHS0017013 in late March 2026 to gather market intelligence on direct-to-manufacturer prescription programs without a formal competitive timeline, signaling early-stage procurement planning rather than imminent award activity.